Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 31
Back to Home
Sermorelin
EfficacyHigh
Studies12
Participants450
StatusAvailable

Sermorelin

Sermorelin acetate (GHRH 1-29)

Sermorelin is a synthetic 29-amino acid peptide that mimics the biologically active portion of growth hormone releasing hormone (GHRH). Originally FDA-approved in 1997 as Geref® for treating children with growth hormone deficiency, it stimulates the pituitary gland to produce natural growth hormone in physiological pulsatile patterns. Unlike direct growth hormone injections, sermorelin works with the body's feedback mechanisms to prevent overdose and maintain natural GH rhythms.

Complete Research Database

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

Sermorelin functions as a synthetic analog of the first 29 amino acids of endogenous growth hormone releasing hormone (GHRH). It binds specifically to GHRH receptors (GHRHR) on somatotroph cells of the anterior pituitary gland, activating adenylyl cyclase and increasing intracellular cAMP levels. This cascade stimulates transcription of the growth hormone gene and promotes GH synthesis and secretion in natural pulsatile patterns. The physiological regulation via somatostatin feedback prevents excessive GH release and maintains the integrity of the growth hormone neuroendocrine axis, unlike exogenous recombinant GH administration.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Growth hormone-releasing hormone analogs in children with growth hormone deficiency

Read
Journal of Clinical Endocrinology & Metabolism (1997)
N = 127
High Impact
152% increase in growth velocity with sermorelin treatment
DOI: 10.1210/jcem.82.2.3729

Diagnostic utility of GHRH stimulation testing versus insulin tolerance testing

Read
Clinical Endocrinology (1998)
N = 89
High Impact
98% diagnostic accuracy for growth hormone deficiency
DOI: 10.1046/j.1365-2265.1998.00426.x

Adult growth hormone insufficiency: observational study of sermorelin therapy

Read
Hormone Research in Paediatrics (2019)
N = 234
Medium Impact
12.3% increase in lean mass, improved quality of life
DOI: 10.1159/000502456
Additional research available through PubMed and other scientific databases.

Medical Disclaimer

Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.